Table 1. Correlation between the clinical pathological factors and expression of miR-374a, CCND1 in CRC.
| The expression of miR-374a and CCND1 | |||||||
|---|---|---|---|---|---|---|---|
| Clinical parameter | n | HH (n, %) | HL (n, %) | LH (n, %) | LL (n, %) | χ2 value | P value |
| gender | |||||||
| male | 48 | 11 (22.9) | 6 (12.5) | 20 (41.7) | 11 (22.9) | 4.218 | 0.239 |
| female | 42 | 12 (28.6) | 1 (2.4) | 22 (52.4) | 7 (16.7) | ||
| age (year) | |||||||
| > 65 | 52 | 13 (25) | 5 (9.6) | 24 (46.2) | 10 (19.2) | 10.028 | 0.018 |
| ≤ 65 | 38 | 10 (26.3) | 2 (5.3) | 18 (47.4) | 8 (21.1) | ||
| T stage | |||||||
| T1–T2 | 15 | 2 (13.3) | 1 (6.7) | 9 (60.0) | 3 (20.0) | 1.766 | 0.622 |
| T3–T4 | 75 | 21 (28.0) | 6 (8.0) | 33 (44.0) | 15 (20.0) | ||
| N stage | |||||||
| N0 | 58 | 13 (22.4) | 6 (10.3) | 30 (51.7) | 9 (15.5) | 4.545 | 0.208 |
| N1–N2 | 32 | 10 (31.2) | 1 (3.1) | 12 (37.5) | 9 (28.1) | ||
| pathological grading | |||||||
| I–II | 48 | 13 (27.1) | 4 (8.3) | 24 (50.0) | 7 (14.6) | 1.889 | 0.596 |
| III–IV | 42 | 10 (23.8) | 3 (7.1) | 18 (42.9) | 11 (26.2) | ||
*
HH represents high miR-374a with high CCND1 expression, HL represents high miR-374a with low CCND1 expression, LH represents low miR-374a with high CCND1 expression, LL represents low miR-374a with low CCND1 expression.